Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis

Hepatology Research

Volumn 44, Issue 9, 2014, Pages 1008-1018

  Matteucci, Claudia ^a,b   Sorrentino, Roberta ^a,b   Bellis, Lia ^c   Ettorre, Giuseppe Maria ^d   Svicher, Valentina ^a   Santoro, Roberto ^d   Vennarecci, Giovanni ^d   Biasiolo, Alessandra ^f   Pontisso, Patrizia ^f   Scacciatelli, Daria ^b   Beneduce, Luca ^g   Sarrecchia, Cesare ^e   Casalino, Paolo ^e   Bernardini, Sergio ^a   Pierimarchi, Pasquale ^b   Garaci, Enrico ^a   Puoti, Claudio ^c   Rasi, Guido ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c Marino Hospital Rome   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g Xeptagen SpA   (Italy)

Author keywords

Disease biomarkers; Hepatitis C; Hepatocellular carcinoma; Immune complexes; Liver cirrhosis; Survivin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; IMMUNOGLOBULIN M; SURVIVIN;

ADULT; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 84907868260     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12239     Document Type: Article

References (46)

1. Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011; 6 (Suppl 1): S93-S98.
2. Cabibbo G, Craxì A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010; 14: 352-355.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr. Accessed September 3, 2013.
4. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl 1): S20-S37.
5. Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 418-424.
6. Sherman M. Hepatocellular carcinoma: new and emerging risks. Dig Liver Dis 2010; 42 (Suppl 3): S215-S222.
7. Degos F, Perez P, Roche B etal. Diagnostic accuracy of Fibroscan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-1021.
8. Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25: 291-303.
9. Rasi G, Serafino A, Bellis L etal. Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2007; 13: 4986-4995.
10. Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011; 49: 959-966.
11. Serafino A, Pierimarchi P. New Molecular Biomarkers Candidates for the Development of Multiparametric Platforms for Hepatocellular Carcinoma Diagnosis, Prognosis and Personalised Therapy. Hepatocellular Carcinoma - Basic Research, Lau W-Y, ed. Rijeka, Croatia: InTech, 2012. ISBN: 978-953-51-0023-2.
12. Beneduce L, Castaldi F, Marino M etal. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005; 103: 2558-2565.
13. Pontisso P, Quarta S, Caberlotto C etal. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006; 119: 735-740.
14. Biasiolo A, Chemello L, Quarta S etal. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008; 15: 246-249.
15. Beneduce L, Pesce G, Gallotta A etal. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 2008; 38: 571-577.
16. Jiang J, Wu C, Shen Y etal. Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma. Anticancer Res 2011; 31: 687-691.
17. Lacroix-Desmazes S, Kaveri SV, Mouthon L etal. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998; 216: 117-137.
18. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010; 10: 778-786.
19. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and ymphoma. Nat Med 1997; 3: 917-921.
20. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14: 5000-5005.
21. Cheung CHA, Cheng LT, Chang KY, Chen HH, Chang JY. Investigations of survivin: the past, present and future. Front Biosci 2011; 16: 952-961.
22. Ito T, Shiraki K, Sugimoto K etal. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-1085.
23. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004; 17: 1378-1385.
24. Chau GY, Lee AF, Tsay SH etal. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 2007; 51: 204-218.
25. Stefano JT, De Oliveira CPMS, Correâ-Giannella ML etal. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Liver Int 2011; 31: 377-385.
26. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-1426.
27. Zhao X, Ogunwobi OO, Liu C. Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells. PLoS ONE 2011; 6: e21980.
28. Yagihashi A, Asanuma K, Kobayashi D etal. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity 2005; 38: 445-448.
29. Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y, Chan EK. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 2007; 46: 107-114.
30. El-Attar HA, Kandil MH, El-Kerm YM, El-Ghandour MK. Comparison of serum survivin and alpha fetoprotein in Egyptian patients with hepatocellular carcinoma associated with hepatitis C viral infection. Asian Pac J Cancer Prev 2010; 11: 897-903.
31. Moon WS, Tarnawski AS. Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Hum Pathol 2003; 34: 1119-1126.
32. Takashima H, Nakajima T, Moriguchi M etal. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int 2005; 25: 77-84.
33. Morinaga S, Nakamura Y, Ishiwa N etal. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004; 12: 1189-1194.
34. Llovet JM, Chen Y, Wurmbach E etal. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767.
35. Montorsi M, Maggioni M, Falleni M etal. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 2007; 5: 2040-2044.
36. Augello C, Caruso L, Maggioni M etal. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009; 9: 125.
37. Ye CP, Qiu CZ, Huang ZX etal. Relationship between survivin expression and recurrence, and prognosis in hepatocellular carcinoma. World J Gastroenterol 2007; 13: 6264-6268.
38. Peroukides S, Bravou V, Alexopoulos A, Varakis J, Kalofonos H, Papadaki H. Survivin overexpression in HCC and liver cirrhosis differentially correlates with p-STAT3 and E-cadherin. Histol Histopathol 2010; 25: 299-307.
39. Baba HA, Wohlschlaeger J, Schmitz KJ etal. Survivin is upregulated during liver regeneration in rats and humans and is associated with hepatocyte proliferation. Liver Int 2009; 29: 585-592.
40. Hagemann S, Wohlschlaeger J, Bertram S etal. Loss of Survivin influences liver regeneration and is associated with impaired Aurora B function. Cell Death Differ 2013; 20: 834-844.
41. Zhang X, Frank AC, Gille CM etal. Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis. Hepatol Res 2009; 39: 1178-1189.
42. Jiang YF, He B, Li NP, Ma J, Gong GZ, Zhang M. The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-κB pathways. Cell Biol Int 2011; 35: 1225-1232.
43. Rosa D, Saletti G, De Gregorio E etal. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005; 102: 18544-18549.
44. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
45. Valiante NM, D'Andrea A, Crotta S etal. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 2000; 174: 77-89.
46. Mondelli MU. Multifaceted functions of B cells in chronic hepatitis C virus infection. Antiviral Res 2003; 60: 111-115.